Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Muir

Showing results (441-450 of 494) with videos related to

Pageof 50
Sort By:
Hepatology (Baltimore, Md.)|January 29, 2011
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVRAlexander J Thompson, Rosanna Santoro, Valeria Piazzolla, et al.
Hepatology (Baltimore, Md.)|November 21, 2017
Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PROZobair M Younossi, Arian Afendy, Maria Stepanova, et al.
The New England Journal of Medicine|April 9, 2010
Telaprevir for previously treated chronic HCV infectionJohn G McHutchison, Michael P Manns, Andrew J Muir, et al.
Nature|February 23, 2010
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis CJacques Fellay, Alexander J Thompson, Dongliang Ge, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 1, 2008
A common variant in the 3'UTR of the GRIK4 glutamate receptor gene affects transcript abundance and protects against bipolar disorderB S Pickard, H M Knight, R S Hamilton, et al.
Hepatology (Baltimore, Md.)|December 6, 2019
A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C InfectionRae Jean Proeschold-Bell, Donna M Evon, Jia Yao, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 9, 2014
Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL studyMichael T Melia, Norbert Bräu, Fred Poordad, et al.
Hepatology (Baltimore, Md.)|November 9, 2015
Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 dataJulius M Wilder, Lennox J Jeffers, Natarajan Ravendhran, et al.
Molecular Psychiatry|August 23, 2006
Evidence implicating BRD1 with brain development and susceptibility to both schizophrenia and bipolar affective disorderJ E Severinsen, C R Bjarkam, S Kiaer-Larsen, et al.
Hepatology (Baltimore, Md.)|June 22, 2010
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infectionAndrew J Muir, Mitchell L Shiffman, Atif Zaman, et al.
Pageof 50

Showing results (441-450 of 494) with videos related to

Sort By:
Pageof 50
Hepatology (Baltimore, Md.)|January 29, 2011
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVRAlexander J Thompson, Rosanna Santoro, Valeria Piazzolla, et al.
Hepatology (Baltimore, Md.)|November 21, 2017
Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PROZobair M Younossi, Arian Afendy, Maria Stepanova, et al.
The New England Journal of Medicine|April 9, 2010
Telaprevir for previously treated chronic HCV infectionJohn G McHutchison, Michael P Manns, Andrew J Muir, et al.
Nature|February 23, 2010
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis CJacques Fellay, Alexander J Thompson, Dongliang Ge, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 1, 2008
A common variant in the 3'UTR of the GRIK4 glutamate receptor gene affects transcript abundance and protects against bipolar disorderB S Pickard, H M Knight, R S Hamilton, et al.
Hepatology (Baltimore, Md.)|December 6, 2019
A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C InfectionRae Jean Proeschold-Bell, Donna M Evon, Jia Yao, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 9, 2014
Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL studyMichael T Melia, Norbert Bräu, Fred Poordad, et al.
Hepatology (Baltimore, Md.)|November 9, 2015
Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 dataJulius M Wilder, Lennox J Jeffers, Natarajan Ravendhran, et al.
Molecular Psychiatry|August 23, 2006
Evidence implicating BRD1 with brain development and susceptibility to both schizophrenia and bipolar affective disorderJ E Severinsen, C R Bjarkam, S Kiaer-Larsen, et al.
Hepatology (Baltimore, Md.)|June 22, 2010
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infectionAndrew J Muir, Mitchell L Shiffman, Atif Zaman, et al.
Pageof 50